Management of Orthopaedic Tumours

Faculty:

• Rob Grimer

  Royal Orthopaedic Hospital, Birmingham, UK.

• Henrik Bauer

  Karolinska Institute, Stockholm, Sweden.

• Stephen Cannon

  Royal National Orthopaedic Hospital, Stanmore, London, UK.

• Dundar Sabah

  Ege University, Izmir, Turkey.

• Marco Manfrini

  The Rizzoli Institute, Rizzoli Italy.

• Coonoor Chandrasekar

  RLBHT, Liverpool, UK.

• Ajay Puri

  TMC, Mumbai, India.

• Eduardo Yonamine

  Santa Casa Medical School of Sao Paulo, Sao Paulo, Brazil.

• Franklin Sim

  Mayo Clinic, Rochester, MN.

Expiration: 01/26/2016

Location: Online

Requirements for successful completion: In order to receive credit, participants must view all audio-visual presentations and complete both the pre-test, post-test and evaluation form. Participants must score 100% on the activity post-test in order to receive credit. There are no pre-requisites for this activity. Course attendance verification forms are provided upon successful completion of the post-test and evaluation form. No partial credit will be given.

Target Audience: Physicians, residents and trainees, fellows, nurses, surgical techs, physical therapists, and other members of the allied health community whose scope of practice encompasses Orthopaedics.

Course Description: In this live webinar, expert Foot & Ankle, Adult Reconstruction, Oncology, Healthcare Policy will present optimal operable techniques and treatment options to address Management and Treatment of Orthopaedic Tumors. The webinar features time for interactive audience discussion and surgical case based scenarios.

Learning Objectives: Upon completion of this activity, participants should be better able to discuss:

1. Discuss the management of bone sarcomas and bone disease
2. Discuss the use of endoprostheses in the treatment of orthopaedic tumors
3. Discuss the use of irradiated grafts in the treatment of orthopaedic tumors
4. Discuss the management and treatment of soft tissue sarcomas and tumors in children
5. Discuss new innovations in tumor management and treatment

Credits: This lecture qualifies for 2 CME credit hours.

Cost: $0.0

Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the International Institute for Continuing Medical Education and VuMedi. The International Institute for Continuing Medical Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide medical education to physicians.

Designation Statement: The International Institute for Continuing Medical Education, Inc designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures: Faculty Disclosures/Conflict of Interest Policy\nIn accordance with ACCME requirements, The International Institute for Continuing Medical Education, Inc, has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. The relationships were reviewed by The International Institute for Continuing Medical Education, Inc. and conflicts of interest were resolved prior to the activity.

Dr. Rob Grimer discloses the following relevant financial relationships with a commercial interest: Has been on a medical advisory board for Amgen regarding the drug Densoumab. This has revolutionised the management of Giant Cell Tumours of bone- which he will referring to in his talk. He has recently been lead author in an Interntaional Consensus document written separte from the company on this topic.

Dr. Henrik Bauer discloses he has no relevant financial relationships with any commercial interests in relation to this activity.

Dr. Stephen Cannon discloses he has no relevant financial relationships with any commercial interests in relation to this activity.

Dr. Dundar Sabah discloses he has no relevant financial relationships with any commercial interests in relation to this activity.

Dr. Marco Manfrini discloses he has no relevant financial relationships with any commercial interests in relation to this activity.

Dr. Coonoor Chandrasekar discloses he has no relevant financial relationships with any commercial interests in relation to this activity.

Dr. Ajay Puri discloses he has no relevant financial relationships with any commercial interests in relation to this activity.

Dr. Eduardo Yonamine discloses he has no relevant financial relationships with any commercial interests in relation to this activity.

Dr. Franklin Sim discloses he has no relevant financial relationships with any commercial interests in relation to this activity.

Faculty Disclosures of Unlabeled Use: The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Dr. Rob Grimer does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Henrik Bauer does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Stephen Cannon does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Dundar Sabah does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Marco Manfrinin does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Coonoor Chandrasekar does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Ajay Puri does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Eduardo Yonamine does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Franklin Sim does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Commercial Support: No commercial support was received for this activity.

Software Requirements: VuMedi Webinars supports the following web browsers (with enabled JavaScript™): Internet Explorer® versions 6.0, 7.0, 8.0, Mozilla Firefox versions 1.0, 2.0, 3.0, and Safari for Mac. Certain educational activities may require additional software to view multimedia, presentation or printable versions of their content. That software may be: Adobe Acrobat®, Adobe® Flash Player, Microsoft® Office PowerPoint, and Microsoft® Office Word.These activities will be marked as such and will provide links to the required software.

Copyright: Any and/or all materials are for the exclusive use of the faculty and participants of the live activity. Any copying, duplicating or reproducing of any and/or all materials by electronic, mechanical or other means for any purpose other than this enduring activity is strictly prohibited without prior written consent of the author of those materials.

Policy on Privacy and Confidentiality: For more information regarding VuMedi's Policy on Privacy and Confidentiality, please visit http://www.vumedi.com/pages/privacy/

To Contact our Accredited Provider: 6438 US Hwy 11
Springville, AL 35146
Phone: (205) 467-0290
Fax: (205) 467-0195
email: iicmemail@gmail.com

For questions regarding this activity, please contact VuMedi: cme@vumedi.com